Acumen Pharmaceuticals (ABOS) presented clinical data for its lead Alzheimer’s candidate sabirnetug at the 12th Annual Cantor Fitzgerald Global Healthcare Conference on September 9, 2026, alongside an updated roadmap for its Phase II trial and next-generation Enhanced Brain Delivery program.
Sabirnetug is a monoclonal antibody designed to target amyloid-beta oligomers, which CEO Dan O’Connell described as "the most toxic species of Aβ." During a question-and-answer session, O’Connell stated the antibody’s selectivity profile may enable greater efficacy and safety in early-stage Alzheimer’s patients compared with existing therapies.
In the Phase I INTERCEPT-AD study, 48 patients were enrolled. Acumen reported a 10,000-fold selectivity for oligomers versus monomers and more than 100-fold selectivity for oligomers versus fibrils and other amyloid species. Safety observations included five total ARIA cases across the 48 subjects, representing a 10.4% incidence rate. Three of those events occurred at the highest dose level of 60 mg/kg, with one rated as moderately symptomatic and involving limb numbness. Among six ApoE4 homozygous patients exposed to sabirnetug, none developed ARIA-E.
President and Chief Development Officer Jim Doherty said the Phase I results established target engagement of oligomers and produced a safety profile that was consistent with the drug’s mechanism. He added that both imaging and fluid biomarkers moved in the intended direction.
The company is advancing to the Phase II ALTITUDE-AD trial, which will enroll approximately 542 subjects across roughly 180 per cohort. The study features three arms—placebo, 35 mg/kg every four weeks, and 50 mg/kg every four weeks—over an 18-month placebo-controlled period. Patient rollover into the open-label extension exceeded 95%. Acumen set a success benchmark of 30% or greater slowing on the ADAS cognitive scale paired with a competitive safety profile. The data readout is expected in the fourth quarter of 2024.
Enrollment for the Phase I study was completed in approximately 10 months.
Looking ahead, Doherty identified two key milestones for the coming year: validation of the oligomer hypothesis through a robust ALTITUDE-AD outcome and first-patient dosing in the second half of 2027 for the Enhanced Brain Delivery program. An IND filing for the EBD platform is targeted for mid-2027.
Acumen’s balance sheet carries a current ratio of 2.47 and negative free cash flow of $92 million over the trailing twelve months. The company’s shares traded around $3.18 to $3.19 at the time of the conference, with Wall Street analyst price targets ranging from $4 to $10 per share.
Also discussed during the session were competitor programs including lecanemab and donanemab, as well as broader Alzheimer’s landscape participants such as Eli Lilly, Eisai, and Biogen.
